Editor-in-Chief: Dr. Gregory A. Poland
Vaccine has an open access mirror journal Vaccine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.
Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed.
Gregory A. Poland
Editor in Chief, Vaccine and Mayo Clinic, USA
Gregory A. Poland, M.D., studies the immunogenetics of vaccine response in adults and children. Dr. Poland and his team within the Vaccine Research Group aim to improve the health of individuals across the world by pursuing challenges posed by infectious diseases and bioterrorism through clinical, laboratory and epidemiologic vaccine research.
View full bio
The Vaccine Research Group uses immunological testing, including serology, cell-mediated immunity, cell culture and cytokine assays; polymerase chain reaction (PCR) techniques and HLA typing for immunogenetic studies; and high-throughput assays, such as next-generation sequencing, transcriptomics, mass spectrometry and proteomic analysis.
Dr. Poland's research has been continuously funded by the National Institutes of Health since 1991.
What is "vaccinomics?"
Coined by Dr. Poland and his team in 2007, the term "vaccinomics" refers to the development of personalized vaccines based on the increased understanding of immune response phenotype-genotype information. Through research, Dr. Poland and his team aim to explain how vaccine-induced immune responses and vaccine-related adverse events may be genetically determined — and therefore predictable.
University of Florence, Italy
Since 2000, Paolo Bonanni is Full Professor of Hygiene in the Faculty of Medicine, University of Florence, Italy. From 2011 to 2019 he has been the Director of the Specialization School for MDs in Hygiene and Preventive Medicine at the University of Florence.
View full bio
His scientific activity has covered the epidemiology and prevention of infectious diseases, particularly viral hepatitis, diphtheria, tetanus, pertussis, influenza, measles, rubella, varicella, and, most recently, bacterial invasive diseases and HPV, including clinical trials and economic evaluation of vaccination strategies.
He has been a member of the National Vaccination Commission of the Italian Ministry of Health, and he acts as an expert consultant for the European Centre for Disease Prevention and Control (ECDC) based in Stockholm.
He has been a member of the European Technical Group of Experts on Immunization (ETAGE) at WHO Euro, Copenhagen, from 2012 to 2017. He still collaborates with WHO-EURO and ETAGE on specific projects (i.e. he is a member of the Committee for the Verification of Hepatitis B control at present).
He is standing adviser of the Viral Hepatitis Prevention Board (VHPB), an international independent committee of experts in viral hepatitis prevention, and of the International Human Papilloma Virus Prevention Board an international independent committee of experts on HPV prevention. He received several grants from the Italian Ministry of University and the Italian Ministry of Health (Centre for Disease Control or CCM) on projects regarding vaccine-preventable infections. Paolo Bonanni was research unit leader in 4 EU-funded projects on vaccination, and presently coordinating the University of Florence Unit participating as one of the main partners in the EU Innovative Medicine Initiative on brand-specific influenza vaccination effectiveness named DRIVE (Development of Robust Influenza Vaccine Effectiveness).
Paolo Bonanni is the author or co-author of 300 scientific papers published in international and national journals.
Sylvia van den Hurk
Abstract submission deadline – 17 April 2020
Author notification deadline – 5 June 2020
Author registration deadline - 24 July 2020
Early bird deadline – 24 July 2020
Joint Vaccine Resource Center: vaccinesafetyresource.elsevier.com